Genetic and pharmacological downregulation of histone deacetylase 10 (HDAC10) has been shown to decrease lysosomal exocytosis and sensitize doxorubicin-resistant neuroblastoma cells to doxorubicin-induced killing, illustrating the possibility of restoring chemosensitivity by disrupting lysosomal exocytosis [133]. The gene discussed is HDAC10; the disease is neuroblastoma.